Diabetic Nephropathy - Pipeline Review, H1 2016

Published: Feb, 2016 | Pages: 251 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Diabetic Nephropathy - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Diabetic Nephropathy - Pipeline Review, H1 2016', provides an overview of the Diabetic Nephropathy pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Diabetic Nephropathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Diabetic Nephropathy and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Diabetic Nephropathy
- The report reviews pipeline therapeutics for Diabetic Nephropathy by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Diabetic Nephropathy therapeutics and enlists all their major and minor projects
- The report assesses Diabetic Nephropathy therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Diabetic Nephropathy

Reasons to Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Diabetic Nephropathy
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Diabetic Nephropathy pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Diabetic Nephropathy Overview 10
Therapeutics Development 11
Pipeline Products for Diabetic Nephropathy - Overview 11
Pipeline Products for Diabetic Nephropathy - Comparative Analysis 12
Diabetic Nephropathy - Therapeutics under Development by Companies 13
Diabetic Nephropathy - Therapeutics under Investigation by Universities/Institutes 16
Diabetic Nephropathy - Pipeline Products Glance 17
Late Stage Products 17
Clinical Stage Products 18
Early Stage Products 19
Unknown Stage Products 20
Diabetic Nephropathy - Products under Development by Companies 21
Diabetic Nephropathy - Products under Investigation by Universities/Institutes 25
Diabetic Nephropathy - Companies Involved in Therapeutics Development 26
AbbVie Inc. 26
Antisense Therapeutics Limited 27
Arena Pharmaceuticals, Inc. 28
Astellas Pharma Inc. 29
AstraZeneca Plc 30
Bayer AG 31
BiOrion Technologies B.V. 32
Boehringer Ingelheim GmbH 33
Cellmid Limited 34
ChemoCentryx, Inc. 35
Concert Pharmaceuticals, Inc. 36
CSL Limited 37
Daiichi Sankyo Company, Limited 38
Dimerix Bioscience Pty Ltd 39
Dong Wha Pharma Co., Ltd. 40
Dynamis Therapeutics, Inc. 41
Eli Lilly and Company 42
Galectin Therapeutics, Inc. 43
GenKyoTex S.A. 44
Gilead Sciences, Inc. 45
GlaxoSmithKline Plc 46
Glucox Biotech AB 47
GNI Group Ltd. 48
Islet Sciences, Inc. 49
Jenrin Discovery, Inc. 50
Johnson & Johnson 51
Mallinckrodt Plc 52
Mesoblast Limited 53
Mitsubishi Tanabe Pharma Corporation 54
MorphoSys AG 55
NephroGenex, Inc. 56
Noxxon Pharma AG 57
Omeros Corporation 58
Otsuka Holdings Co., Ltd. 59
Pfizer Inc. 60
PhytoHealth Corporation 61
ProMetic Life Sciences Inc. 62
Serodus ASA 63
Shire Plc 64
Takeda Pharmaceutical Company Limited 65
Theravance Biopharma, Inc. 66
Tobira Therapeutics, Inc. 67
Vascular Pharmaceuticals, Inc. 68
Vicore Pharma AB 69
XOMA Corporation 70
Diabetic Nephropathy - Therapeutics Assessment 71
Assessment by Monotherapy Products 71
Assessment by Target 72
Assessment by Mechanism of Action 75
Assessment by Route of Administration 78
Assessment by Molecule Type 80
Drug Profiles 82
11-RVIVIT - Drug Profile 82
A-717 - Drug Profile 83
Antibodies to Inhibit Heparanase for Cancer - Drug Profile 84
APD-371 - Drug Profile 85
APX-115 - Drug Profile 86
ASP-8232 - Drug Profile 87
ATL-1103 - Drug Profile 88
atrasentan hydrochloride - Drug Profile 90
baricitinib - Drug Profile 91
BI-703704 - Drug Profile 94
Biologic for Diabetic Nephropathy - Drug Profile 95
BOT-191 - Drug Profile 96
C-21 - Drug Profile 97
canagliflozin - Drug Profile 99
CCX-140 - Drug Profile 101
cenicriviroc mesylate - Drug Profile 103
corticotropin - Drug Profile 105
CS-3150 - Drug Profile 107
CSL-346 - Drug Profile 109
CTP-499 - Drug Profile 110
Cyndacel-M - Drug Profile 112
DMX-250 - Drug Profile 114
Drugs to Activate Nrf2 for Diabetic Cardiomyopathy and Metabolic Disorders - Drug Profile 115
DT-23552 - Drug Profile 116
DW-1029M - Drug Profile 117
DYN-12 - Drug Profile 118
emapticap pegol - Drug Profile 120
finerenone - Drug Profile 122
gevokizumab - Drug Profile 123
GKT-136901 - Drug Profile 127
GKT-831 - Drug Profile 129
GRMD-02 - Drug Profile 130
GW-610742 - Drug Profile 133
JD-5037 - Drug Profile 134
JNJ-39933673 - Drug Profile 135
Monoclonal Antibodies to Inhibit MASP-2 for Rheumatoid Arthritis and Diabetic Complications - Drug Profile 136
Monoclonal Antibody to Inhibit Midkine for Cancer, Metabolic Disorders and Kidney Diseases - Drug Profile 138
MOR-107 - Drug Profile 140
MPC-300IV - Drug Profile 141
MT-3995 - Drug Profile 143
Nephrilin - Drug Profile 144
oxypurinol - Drug Profile 145
PBI-4050 - Drug Profile 146
PBI-4547 - Drug Profile 148
PF-00489791 - Drug Profile 149
PHN-033 - Drug Profile 150
pirfenidone - Drug Profile 151
probucol - Drug Profile 152
Pyridoxamine Dihydrochloride - Drug Profile 153
selonsertib - Drug Profile 156
SER-150 - Drug Profile 157
SHP-627 - Drug Profile 159
Small Molecule to Inhibit NOX-4 for Diabetic Nephropathy - Drug Profile 160
Small Molecules for Diabetic Nephropathy - Drug Profile 161
Small Molecules for Ophthalmology, Cardiovascular, CNS and Metabolic Disorders - Drug Profile 162
Small Molecules to Inhibit Heparanase for Metastatic Cancer and Diabetic Nephropathy - Drug Profile 164
SP-20202 - Drug Profile 165
TAK-272 - Drug Profile 166
TAK-648 - Drug Profile 167
TBE-31 - Drug Profile 168
TD-0714 - Drug Profile 169
VPI-2690B - Drug Profile 170
VS-105 - Drug Profile 172
XRX-108 - Drug Profile 173
XRX-221 - Drug Profile 174
Diabetic Nephropathy - Recent Pipeline Updates 175
Diabetic Nephropathy - Dormant Projects 233
Diabetic Nephropathy - Discontinued Products 236
Diabetic Nephropathy - Product Development Milestones 237
Featured News & Press Releases 237
Appendix 245
Methodology 245
Coverage 245
Secondary Research 245
Primary Research 245
Expert Panel Validation 245
Contact Us 245
Disclaimer 246

List of Tables
Number of Products under Development for Diabetic Nephropathy, H1 2016 16
Number of Products under Development for Diabetic Nephropathy - Comparative Analysis, H1 2016 17
Number of Products under Development by Companies, H1 2016 18
Number of Products under Development by Companies, H1 2016 (Contd..1) 19
Number of Products under Development by Companies, H1 2016 (Contd..2) 20
Number of Products under Investigation by Universities/Institutes, H1 2016 21
Comparative Analysis by Late Stage Development, H1 2016 22
Comparative Analysis by Clinical Stage Development, H1 2016 23
Comparative Analysis by Early Stage Development, H1 2016 24
Comparative Analysis by Unknown Stage Development, H1 2016 25
Products under Development by Companies, H1 2016 26
Products under Development by Companies, H1 2016 (Contd..1) 27
Products under Development by Companies, H1 2016 (Contd..2) 28
Products under Development by Companies, H1 2016 (Contd..3) 29
Products under Investigation by Universities/Institutes, H1 2016 30
Diabetic Nephropathy - Pipeline by AbbVie Inc., H1 2016 31
Diabetic Nephropathy - Pipeline by Antisense Therapeutics Limited, H1 2016 32
Diabetic Nephropathy - Pipeline by Arena Pharmaceuticals, Inc., H1 2016 33
Diabetic Nephropathy - Pipeline by Astellas Pharma Inc., H1 2016 34
Diabetic Nephropathy - Pipeline by AstraZeneca Plc, H1 2016 35
Diabetic Nephropathy - Pipeline by Bayer AG, H1 2016 36
Diabetic Nephropathy - Pipeline by BiOrion Technologies B.V., H1 2016 37
Diabetic Nephropathy - Pipeline by Boehringer Ingelheim GmbH, H1 2016 38
Diabetic Nephropathy - Pipeline by Cellmid Limited, H1 2016 39
Diabetic Nephropathy - Pipeline by ChemoCentryx, Inc., H1 2016 40
Diabetic Nephropathy - Pipeline by Concert Pharmaceuticals, Inc., H1 2016 41
Diabetic Nephropathy - Pipeline by CSL Limited, H1 2016 42
Diabetic Nephropathy - Pipeline by Daiichi Sankyo Company, Limited, H1 2016 43
Diabetic Nephropathy - Pipeline by Dimerix Bioscience Pty Ltd, H1 2016 44
Diabetic Nephropathy - Pipeline by Dong Wha Pharma Co., Ltd., H1 2016 45
Diabetic Nephropathy - Pipeline by Dynamis Therapeutics, Inc., H1 2016 46
Diabetic Nephropathy - Pipeline by Eli Lilly and Company, H1 2016 47
Diabetic Nephropathy - Pipeline by Galectin Therapeutics, Inc., H1 2016 48
Diabetic Nephropathy - Pipeline by GenKyoTex S.A., H1 2016 49
Diabetic Nephropathy - Pipeline by Gilead Sciences, Inc., H1 2016 50
Diabetic Nephropathy - Pipeline by GlaxoSmithKline Plc, H1 2016 51
Diabetic Nephropathy - Pipeline by Glucox Biotech AB, H1 2016 52
Diabetic Nephropathy - Pipeline by GNI Group Ltd., H1 2016 53
Diabetic Nephropathy - Pipeline by Islet Sciences, Inc., H1 2016 54
Diabetic Nephropathy - Pipeline by Jenrin Discovery, Inc., H1 2016 55
Diabetic Nephropathy - Pipeline by Johnson & Johnson, H1 2016 56
Diabetic Nephropathy - Pipeline by Mallinckrodt Plc, H1 2016 57
Diabetic Nephropathy - Pipeline by Mesoblast Limited, H1 2016 58
Diabetic Nephropathy - Pipeline by Mitsubishi Tanabe Pharma Corporation, H1 2016 59
Diabetic Nephropathy - Pipeline by MorphoSys AG, H1 2016 60
Diabetic Nephropathy - Pipeline by NephroGenex, Inc., H1 2016 61
Diabetic Nephropathy - Pipeline by Noxxon Pharma AG, H1 2016 62
Diabetic Nephropathy - Pipeline by Omeros Corporation, H1 2016 63
Diabetic Nephropathy - Pipeline by Otsuka Holdings Co., Ltd., H1 2016 64
Diabetic Nephropathy - Pipeline by Pfizer Inc., H1 2016 65
Diabetic Nephropathy - Pipeline by PhytoHealth Corporation, H1 2016 66
Diabetic Nephropathy - Pipeline by ProMetic Life Sciences Inc., H1 2016 67
Diabetic Nephropathy - Pipeline by Serodus ASA, H1 2016 68
Diabetic Nephropathy - Pipeline by Shire Plc, H1 2016 69
Diabetic Nephropathy - Pipeline by Takeda Pharmaceutical Company Limited, H1 2016 70
Diabetic Nephropathy - Pipeline by Theravance Biopharma, Inc., H1 2016 71
Diabetic Nephropathy - Pipeline by Tobira Therapeutics, Inc., H1 2016 72
Diabetic Nephropathy - Pipeline by Vascular Pharmaceuticals, Inc., H1 2016 73
Diabetic Nephropathy - Pipeline by Vicore Pharma AB, H1 2016 74
Diabetic Nephropathy - Pipeline by XOMA Corporation, H1 2016 75
Assessment by Monotherapy Products, H1 2016 76
Number of Products by Stage and Target, H1 2016 78
Number of Products by Stage and Mechanism of Action, H1 2016 81
Number of Products by Stage and Route of Administration, H1 2016 84
Number of Products by Stage and Molecule Type, H1 2016 86
Diabetic Nephropathy Therapeutics - Recent Pipeline Updates, H1 2016 180
Diabetic Nephropathy - Dormant Projects, H1 2016 238
Diabetic Nephropathy - Dormant Projects (Contd..1), H1 2016 239
Diabetic Nephropathy - Dormant Projects (Contd..2), H1 2016 240
Diabetic Nephropathy - Discontinued Products, H1 2016 241